![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 41, 38242-38248, October 12, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,From the Life Sciences Division, Department of Molecular and Cellular Biology, Lawrence Berkeley National Laboratory, Berkeley, California 94720
Received for publication, March 2, 2001, and in revised form, July 26, 2001
| |
ABSTRACT |
|---|
|
|
|---|
DNA double-strand breaks (DSBs) are a highly
mutagenic and potentially lethal damage that occurs in all organisms.
Mammalian cells repair DSBs by homologous recombination and
non-homologous end joining, the latter requiring
DNA-dependent protein kinase (DNA-PK). Werner syndrome is a
disorder characterized by genomic instability, aging pathologies and
defective WRN, a RecQ-like helicase with exonuclease activity. We show
that WRN interacts directly with the catalytic subunit of DNA-PK
(DNA-PKCS), which inhibits both the helicase and
exonuclease activities of WRN. In addition we show that WRN forms a
stable complex on DNA with DNA-PKCS and the DNA binding
subunit Ku. This assembly reverses WRN enzymatic inhibition. Finally,
we show that WRN is phosphorylated in vitro by DNA-PK and
requires DNA-PK for phosphorylation in vivo, and that cells
deficient in WRN are mildly sensitive to ionizing radiation. These data
suggest that DNA-PK and WRN may function together in DNA
metabolism and implicate WRN function in non-homologous end joining.
The rapid recognition and repair of DNA damage is essential for
the maintenance of genomic integrity and cellular survival. DNA
double-strand breaks (DSBs)1
are particularly mutagenic when misrepaired and lethal if unrepaired. DSBs are introduced into the genome by several means, including errors
in DNA metabolism, ionizing radiation, oxidative damage, and
radiomimetic drugs. Many cancer therapies exploit the lethality of DNA
DSBs by chemically or physically inflicting this type of damage on
cancer cells. Eukaryotic cells have evolved two major pathways to
repair DSBs: homologous recombination and nonhomologous end joining
(NHEJ). Both pathways contribute significantly to the repair of DSBs
and the viability of cells encountering this type of damage (1).
The DNA-dependent protein kinase (DNA-PK) is a key
component of the mammalian NHEJ repair pathway. DNA-PK is an abundant
nuclear serine/threonine protein kinase consisting of a 460-kDa
catalytic subunit, DNA-PKCS, and a DNA binding component,
Ku. Ku is a heterodimer comprising 69-kDa (Ku70) and 86-kDa (Ku80)
subunits (2). The Ku heterodimer binds tightly to DNA DSBs in a
sequence-independent manner (3). The kinase function of
DNA-PKCS is activated when DNA-PKCS associates
with Ku bound to DNA termini. In vitro, the heterotrimeric
DNA-PK bound to DNA is capable of phosphorylating a wide variety of
substrates, but in vivo substrates for DNA-PK have yet to be
clearly identified (4). Disruption of any of the three genes encoding
DNA-PK components, or mutations rendering the kinase inactive, result
in severely compromised NHEJ and V(D)J recombination and, in the case
of the Ku deficiencies, premature cellular and organismal senescence
(5-8). Although DNA-PK and its kinase activity are clearly required
for mammalian NHEJ, the specific biochemical function(s) of DNA-PK
in vivo have yet to be defined.
Werner syndrome (WS) is an autosomal recessive disorder, characterized
at the cellular level by genomic instability in the form of variegated
translocation mosaicism and extensive deletions (9, 10). Individuals
with WS prematurely develop multiple age-related pathologies including
bilateral cataracts, graying of the hair, wrinkled skin, osteoporosis,
type II diabetes, atherosclerosis, and increased incidence of cancer
(11, 12). WRN, the gene defective in WS, encodes a 160-kDa
protein (WRN), which has 3'-5' exonuclease, DNA helicase, and
DNA-dependent ATPase activities (13, 14). WRN has been
reported to interact with p53, replication protein A (RPA),
proliferating cell nuclear antigen (PCNA), and DNA polymerase
Repair of DSBs via NHEJ minimally requires DNA-PK and ligase activity,
and frequently a search for microhomology, which may require helicase
activity, and exonuclease activity (18). Ligase IV has been identified
by genetic and biochemical studies to be the relevant ligase in NHEJ
(19), but the enzymes responsible for the exonuclease and helicase
activities have not been identified. The Mre11·Rad50·NBS1 complex
has been implicated in providing the exonuclease activity involved in
the NHEJ, but recent reports suggest that this complex may function
primarily in homologous recombination repair, with secondary roles in
NHEJ and damage signaling (20, 21). Because WRN has both helicase and
exonuclease activities, it could facilitate both the microhomology
search and the removal of bases prior to the ligation step of NHEJ.
In this study, we utilize biochemical and cellular approaches to
evaluate interactions between DNA-PK and the WRN protein. We show
functional and physiological interactions between DNA-PK and WRN. These
results provide a mechanistic model for the regulation of WRN activity
by DNA-PK. Our results further suggest that WRN and DNA-PK may function
together in DNA metabolism.
Cell Lines, and Clonogenic and Viability Assays--
WS (73-26)
and fibroblasts from a normal sibling (82-6) were infected with a pBABE
retrovirus carrying the catalytic component of human telomerase (hTERT)
and a puromycin resistance gene, selected, and expanded as described
(22). Cultures infected with insertless virus senesced 10 (73-26) and
40 (82-6) doublings after infection, whereas cultures infected with
pBABE-hTERT continued to proliferate for >150 doublings.
Telomerase-expressing cells (73-26 hTERT and 82-6 hTERT) were then
superinfected with an LXSN retrovirus carrying the full-length WRN
cDNA, untagged or FLAG-tagged at the N terminus, and a
neomycin-resistant gene. Infected cells were selected and expanded as
described (22). Cells (82-6 hTERT, 73-26 hTERT, and WRN-complemented
73-26 hTERT) were grown in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum, 4 mM glutamine, and penicillin/streptomycin. For survival assays, varying numbers of
cells (5 × 102 to 2 × 103) were
plated in triplicate 100-mm culture dishes and irradiated 4 h
later (0-5 Gy) using a Pantak® x-ray generator operating
at 320 kV/12 mA. After incubation for 9-15 days, the cells were
stained with crystal violet, colonies were counted, and the surviving
fraction calculated. For viability assays, cells were plated in
triplicate 96-well plates at 1000 cells/well, irradiated as described
above, and 9 days later the relative number of viable cells was
determined using the CellTiter 96® AQueous assay kit
(Promega). This assay is based on cellular conversion of the
tetrazolium salt,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (inner salt) (MTS) to a formazan product that is soluble in culture medium and quantified by absorbance at 490 nm. Absorbance is
proportional to the number of living cells.
Protein Expression and Purification--
WRN and Ku proteins
were purified to near homogeneity from Sf9 insect cells infected
with recombinant baculovirus carrying the respective human genes (14,
23). DNA-PKCS was purified from either human placenta or
cultured HeLa cells, as described previously (24, 25).
Immunoprecipitation and Western Blot Analysis--
Nuclear
extracts were prepared by hypotonic swelling and freeze/thaw lysis of
cells in 20 mM Tris-HCl, pH 8.0, 1 mM
dithiothreitol (DTT). Nuclei were collected by centrifugation at
8000 × g for 5 min, and extracted in 20 mM
Tris-HCl, pH 8.0, 0.5 M NaCl, 5 mM
MgCl2, 10% glycerol, 1 mM DTT for 30 min on
ice. All buffers contained aprotinin, leupeptin, and pepstatin A at 1 µg/ml, and phenylmethylsulfonyl fluoride at 1 mM.
Extracts were clarified by centrifugation at 16,000 × g for 10 min and diluted (1:3) with 20 mM
Tris-HCl pH 8.0. Mouse IgG (1 µg) or 1 µl of rabbit serum was added
to 750 µl of nuclear extract, or 0.5 µg of each purified protein,
in 750 µl of Tris-buffered saline containing 1 µg of a 35-bp
double-stranded DNA oligonucleotide with 5-nucleotide single-strand
extensions on both 5' termini, (5'-GGC GCA AAT CAA CAC GTT GAC TAC CGT
CTT GAG GCA GAG T) (5'-CCG GGA CTC TGC CTC AAG ACG GTA GTC AAC GTG TTG
ATT T) as indicated. Reactions were incubated for 2 h at 4 °C
with gentle agitation. 10 µl of Ultralink Protein A/G beads (Pierce)
was added to the reactions and incubated for 1 h at 4 °C with
gentle agitation. The beads were washed with 0.5 ml of Tris-buffered
saline, 0.5% Nonidet P-40, boiled in SDS-sample buffer, and the
proteins resolved by 6% SDS-PAGE and analyzed by Western blotting
using polyclonal antibodies recognizing WRN (26) or monoclonal
antibodies recognizing DNA-PKCS (25-4) from NeoMarkers
(Fremont, CA).
Electrophoretic Mobility Shift Assays--
Binding reactions
were carried out in 20 mM HEPES, pH 7.5, 50 mM
KCl, 1 mM DTT, and 10% glycerol using 200 fmol of the
35-bp DNA described above. The oligonucleotide was 5'-end labeled on a
single strand with [ Kinase Assays and in Vivo Labeling--
In vitro
kinase assays were carried out as described (29), using ~0.5 pmol
(0.2 pmol for wortmannin experiments) of DNA-PK, 1 pmol of WRN, and
0.75 µg of sheared salmon sperm DNA and 1 µM wortmannin
where noted. Reactions were separated by 7.5% SDS-PAGE, visualized,
and quantified using PhosphorImager and ImageQuant software from
Molecular Dynamics (Sunnyvale, CA). In vivo labeling experiments used exponentially growing cells (Jurkat, M059J, M059K, SV40 transformed AT (AT5BIVA) or wild-type (1BR3.3GN2) human skin fibroblasts). The cells were washed with phosphate-free RPMI, supplemented with 10% fetal bovine serum, and incubated for 30 min at
37 °C in the same media. [32P]Orthophosphate was added
directly to the medium (0.6 mCi/ml), with wortmannin at 20 µM where indicated. After 30 min of incubation at
37 °C, the cells were harvested and lysed in the presence of phosphatase inhibitors (1 mM
Na3VO4, 10 mM NaF, and 75 nM microcystin) as described previously (30). The extracts
were diluted to a final concentration of 100 mM NaCl,
Nonidet P-40 was added (0.5%, final concentration), and WRN was
immunoprecipitated using 0.5 µl of rabbit anti-serum recognizing WRN.
The immunoprecipitated proteins were resolved by SDS-PAGE and analyzed
by autoradiography and Western blotting.
Helicase and Exonuclease Assays--
Helicase reactions were
carried out in 50 mM HEPES (pH 7.5), 5 mM DTT,
0.1 mg/ml bovine serum albumin, and 2 mM ATP with ~100 fmol of a 21-nucleotide/43-nucleotide duplex DNA substrate in which the
21-nucleotide strand was 5'-end labeled with [ WRN Interacts Directly with DNA-PKCS--
To
investigate the possibility that WRN functions in NHEJ, we initially
carried out immunoprecipitations to determine whether WRN associates
with DNA-PK. A rabbit polyclonal antibody recognizing WRN was used to
immunoprecipitate Jurkat cell nuclear extracts. We found that
DNA-PKCS co-precipitated with WRN (Fig.
1A, lane 3). The reciprocal experiment, using a monoclonal antibody
that binds DNA-PKCS, co-precipitated WRN with
DNA-PKCS (Fig. 1A, lane 4). The association of WRN with DNA-PKCS was
confirmed using extracts from HeLa and M059K cells and, therefore, was
not limited to Jurkat cells (data not shown).
The interaction between WRN and DNA-PKCS in cellular
extracts could be mediated by other proteins and/or DNA. We therefore reconstituted this interaction using purified proteins and DNA (Fig.
1B). WRN associated directly with DNA-PKCS,
independent of Ku, and this association was not influenced by the
addition of DNA (Fig. 1B, lanes 1-4).
Additionally, the interaction between DNA-PKCS and WRN was
not disrupted by ethidium bromide (concentrations up to 100 µg/ml),
further indicating that the interaction is direct (data not shown)
(31). Interestingly, a significant and reproducible increase in the
amount of WRN associated with DNA-PKCS was observed when
all four components (WRN, Ku, DNA-PKCS, and DNA) were
present (Fig. 1B, compare lanes 3-5
with lane 6). WRN has been reported to interact
with Ku, and this interaction was shown to stimulate the WRN
exonuclease activity in vitro (16, 17). Here, the addition
of Ku did not appear to influence the association of WRN and
DNA-PKCS in the absence of DNA, indicating that the WRN-Ku interaction did not markedly influence the WRN-DNA-PKCS
interaction (Fig. 1B, compare lane 5 with lanes 3 and 4). These data show that WRN interacts directly with DNA-PKCS, independently of
Ku or DNA, and suggest the formation of a stable
WRN·DNA-PK·DNA complex.
WRN Assembles with DNA-PK on DNA--
To further characterize the
nature of the interaction between DNA-PK and WRN, EMSAs were carried
out using purified proteins. The binding of Ku to DNA is well
characterized and gave the expected mobility shift (Fig. 1C,
lane 2) (32). The addition of equimolar amounts
of purified DNA-PKCS further retarded the mobility of the
probe, indicating the assembly of DNA-PK on the DNA (Fig. 1C, lane 3). The addition of WRN to
the DNA-PK binding reaction retarded the probe even further, indicating
association of WRN with the DNA-PK·DNA complex (Fig. 1C,
lane 4). The addition of WRN appeared to
stabilize the DNA·DNA-PK complex, as evidenced by the distinct
increase in the amount of DNA shifted and decrease in the amounts of
Ku·DNA and DNA-PK·DNA complexes (Fig. 1C, compare lanes 3 and 4). Neither
DNA-PKCS nor WRN alone retarded the probe under these
conditions, indicating that neither protein independently bound DNA
efficiently (Fig. 1C, lanes 5 and
6). Ku plus WRN in the absence of DNA-PKCS gave
only the shifted band corresponding to Ku (data not shown).
To detect complexes such as Ku·WRN, which may dissociate under these
assay conditions, EMSAs were run after cross-linking with
glutaraldehyde (Fig. 1D). Cross-linking of WRN in the
presence of DNA gave only a faint mobility shift, detectable only after long exposures, indicating that its association with DNA is relatively weak (Fig. 1D, lane 1). As expected, reactions
containing Ku and DNA-PKCS gave two bands corresponding to
Ku and assembled DNA-PK (Fig. 1D, lane
2). Cross-linked reactions containing both Ku and WRN are
shown in Fig. 1D (lane 3). The
majority of the shifted DNA had a mobility consistent with the Ku·DNA
complex, with only minor bands consistent with WRN·DNA and
WRN·Ku·DNA complexes. Finally, the cross-linking of DNA-PK·WRN
resolved Ku·DNA, the DNA-PK·DNA complex, and a band with mobility
consistent with the DNA-PK·WRN·DNA complex (Fig. 1D,
lane 4). To confirm the presence of WRN in this
complex, we carried out a mobility shift experiment using antibodies
that recognize WRN. To visualize all three complexes simultaneously, we
cross-linked the reactions before adding increasing amounts of WRN
antibody (Fig. 1D, lanes 2'-5'). In
the presence of WRN antibody, we observe a mobility shift of only the
uppermost band, confirming that WRN is present and exclusive to the
uppermost complex. Taken together, these data show that WRN assembles
with DNA-PK on DNA and the DNA-PK·WRN·DNA ternary complex is more
stable than subcomplexes.
DNA-PKCS Phosphorylates WRN in Vitro and in
Vivo--
We next asked whether WRN is a substrate for DNA-PK kinase
activity. DNA-PK phosphorylated WRN in vitro in a
DNA-dependent manner (Fig.
2A, compare lanes
3 and 4). To confirm that the phosphorylation of
WRN was due to DNA-PK, we tested whether wortmannin, a compound known
to inhibit DNA-PK, could block phosphorylation of WRN. Phosphorylation of WRN was reduced by more than 90% in the presence of 1 µM wortmannin (Fig. 2A, lanes
5 and 6), confirming that WRN is phosphorylated by DNA-PK and that this phosphorylation is inhibited by wortmannin.
DNA-PK has been shown to phosphorylate a variety of substrates in
vitro, many of which have no apparent physiological relevance to
DNA repair (4). To gain insights into whether WRN is a physiological substrate of DNA-PK, we carried out labeling experiments to determine whether phosphorylation of WRN occurs in vivo. Jurkat cells
were starved for phosphate, followed by addition of
[32P]orthophosphate alone or with the
phosphatidylinositol 3-kinase inhibitor wortmannin. Cellular extracts
were prepared, followed by immunoprecipitation of WRN. The
immunoprecipitates were resolved by SDS-PAGE and transferred to a
nitrocellulose membrane. Sequential autoradiography and Western
blotting showed that immunoprecipitated WRN was radiolabeled, clearly
demonstrating that WRN was phosphorylated in vivo (Fig.
2B). Moreover, wortmannin was a potent inhibitor of WRN
phosphorylation in vivo (Fig. 2B,
lanes 1 and 2).
Wortmannin has been reported to act primarily by inhibiting DNA-PK
in vivo (33), but significant inhibition of other members of
the phosphatidylinositol 3-kinase family of kinases has also been
reported (34, 35). To determine whether DNA-PK is required for
phosphorylation of WRN in vivo, the human glioma cell lines M059J (which lack DNA-PKCS) and M059K (which express
DNA-PKCS) were labeled and analyzed as above (36). WRN
immunoprecipitated from 32P-labeled M059K cells was clearly
radiolabeled, whereas WRN immunoprecipitated from
32P-labeled M059J was not (Fig. 2B,
upper panel, lanes 3 and
4). Western blotting showed that equal amounts of WRN
protein were precipitated from M059J and M059K cells (Fig.
2B, bottom panel, lanes
3 and 4). The intensity of minor contaminating
proteins in the immunoprecipitates was independent of the presence of
wortmannin, or DNA-PKCS, indicating that approximately
equal amounts of isotope were internalized by the cells, and that other
kinase activities were not altered (data not shown). The level of
another phosphatidylinositol 3-kinase member, the ataxia-telangiectasia
mutated protein, is low in M059J compared with M059K cells (37). To
determine whether ataxia-telangiectasia mutated protein levels affected
WRN phosphorylation in vivo, we immunoprecipitated WRN from
32P-labeled normal (1BR3.3GN2) and ataxia-telangiectasia
(AT5BIVA) human fibroblasts. WRN phosphorylation was similar in normal
and ataxia-telangiectasia cells (Fig. 2B, lanes
5 and 6). Thus, the difference in the WRN
phosphorylation in M059K and M059J cells was due to the difference in
DNA-PKCS levels. These experiments indicate that DNA-PK is
required for WRN phosphorylation, and there is a physiological
interaction between WRN and DNA-PK in vivo.
DNA-PKCS Inhibits WRN Enzymatic Activities and Ku
Reverses Inhibition--
WRN has both 3'-5' exonuclease and
ATP-dependent helicase activities (13, 14, 38). To
determine the functional significance of the interaction between WRN
and DNA-PK, we first examined the effect of DNA-PK on helicase
activity. Preparations of Ku and DNA-PKCS showed no
detectable helicase or exonuclease activity under our assay conditions
(data not shown). As reported (16), the addition of Ku did not markedly
alter helicase activity (Fig. 3A, lanes
2-5). However, increasing amounts of DNA-PKCS
distinctly inhibited WRN helicase activity (Fig. 3A,
lanes 6-8). This inhibition was relieved by
increasing amounts of Ku (Fig. 3A, lanes
9-11). Because WRN helicase and DNA-PK kinase activities
both require ATP, we used wortmannin to specifically inhibit
phosphorylation during the helicase reaction. The reversal of helicase
inhibition was not altered by wortmannin. Thus, the ability of Ku to
reverse the inhibition of WRN helicase by DNA-PKCS was not
phosphorylation-dependent (Fig. 3A,
lanes 12-14).
We next investigated the effect of DNA-PKCS on WRN
exonuclease activity. Increasing amounts of DNA-PKCS
markedly inhibited the exonuclease activity (Fig. 3B,
lanes 3-6). The addition of Ku to a parallel set
of reactions alleviated this inhibition (Fig. 3B,
lanes 8-11). WRN exonuclease activity was also
stimulated by Ku alone (Fig. 3B, compare lanes
2 and 7), as reported previously (16). This
stimulation is also seen in the helicase assays at high Ku
concentrations (Fig. 3A, lanes 4 and
5; note degradation of the lower band). To determine whether
kinase activity alters WRN exonuclease activity, Ku and ATP were added
to reactions containing WRN and increasing amounts of
DNA-PKCS. ATP stimulated exonuclease activity only slightly
above that caused by Ku alone, suggesting that reversal of inhibition
by Ku is not entirely phosphorylation-dependent (Fig.
3B, compare lanes 8-11 with
lanes 13-16). Taken together, these data show
that WRN helicase and exonuclease activities are inhibited when WRN is
bound to DNA-PKCS, and that this inhibition is reversed
when Ku is added.
WS Cells Are Sensitive to Ionizing Radiation (IR) and Wild-type WRN
Complements Sensitivity--
Together, our data suggest that WRN is
regulated by DNA-PK, raising the possibility that WRN functions in
NHEJ. If WRN functions in NHEJ, its absence should diminish the cell's
capacity for NHEJ, a hallmark of which is sensitivity to IR. WS cells,
whether normal or SV-40 transformed have not been reported to be
IR-sensitive. However, given the relatively mild symptoms of WS,
compared with those in mice deficient in DNA-PK components, WRN may not
play an essential role in NHEJ and WRN deficiency may therefore confer only mild sensitivity to IR.
To test this idea, we immortalized fibroblasts from a WS patient
(73-26) and normal sibling (82-6) by expressing the catalytic subunit
of telomerase (hTERT), as described (22). We then complemented the
immortal WS cells with the wild-type WRN cDNA, either
epitope (FLAG)-tagged or untagged using retroviral transduction and
selection of mass populations. Western analysis showed that WRN was
undetectable in WS cells, expressed in normal (wild-type) cells, and
overexpressed in complemented WS cells (Fig.
4A). Clonogenic survival
assays showed that WS cells (73-26) were more sensitive to IR than
wild-type cells (82-6), although this sensitivity was much less
pronounced than in cells deficient in DNA-PK components (8). Most
important, WS cells that expressed FLAG-tagged WRN protein showed
restoration of wild-type IR sensitivity (Fig. 4B). To
confirm the IR sensitivity of WS cells, we carried out cell
proliferation assays using the MTS assay (39, 40). The results verified
the IR sensitivity of WS cells detected by the clonogenic assay.
Moreover, they showed complementation of the IR sensitivity by untagged
WRN (Fig. 4C). In both assays, we used non-clonal
populations, thus minimizing the possibility of clonal variation in IR
sensitivity, and in the MTS assay, cells infected with an insertless
virus were assayed as a control. Although the IR sensitivity of WS
cells was mild compared with Ku or DNA-PKCS-deficient cell
lines, the sensitivity was complemented by restoration of wild-type WRN
protein.
Our studies show that WRN associates with DNA-PKCS
both in vivo and in vitro, assembles with DNA-PK
on DNA, and forms a stable WRN·DNA-PK·DNA complex. The association
of WRN and DNA-PKCS inhibited both the exonuclease and
helicase activities of WRN, and the addition of Ku and subsequent
formation of the WRN·DNA-PK·DNA complex resulted in active
exonuclease, helicase, and kinase activities. Additionally, WRN was
phosphorylated in vivo in a manner strictly dependent upon
DNA-PKCS, and an absence of WRN protein conferred mild IR sensitivity to cells. Taken together, our data suggest that DNA-PK may
regulate WRN activity and that WRN functions with DNA-PK to process DNA DSBs.
DNA repair is a metabolic necessity of the highest priority, carried
out by a complex network of repair proteins and pathways. The NHEJ
repair pathway repairs a significant proportion of DNA DSBs in higher
eukaryotes (41). Although exonuclease activity in NHEJ has been clearly
demonstrated (42), the lack of exonuclease mutant cell lines exhibiting
severe IR sensitivity suggests redundancy for exonuclease function in
NHEJ. The Mre11·Rad50·NBS1 (M/R/N) complex has been implicated as
functioning directly in NHEJ (43), but other studies indicate DNA-PK
and M/R/N do not associate (44) or co-localize (45) and that Ku
inhibits M/R/N exonuclease activity (46). Consequently, the role of
M/R/N in NHEJ remains unclear. In contrast, Ku has been reported to
interact directly with WRN and stimulate WRN exonuclease activity
suggesting that these proteins function together in DNA metabolism (16,
17). Our data suggest that WRN functions with DNA-PK to facilitate DNA
end processing. It is plausible that both WRN and M/R/N function in
NHEJ by providing exonuclease activities that are partially redundant.
By negatively modulating the exonuclease activity of WRN, DNA-PK may
limit the extent of degradation during NHEJ, thereby preventing
extensive deletions and increasing the fidelity of repair. In the
absence of WRN, other exonucleases that are less regulated may
substitute for this function. Consistent with this idea, mutations at
the HPRT locus show more extensive deletions in WS cells
compared with wild-type cells (10). Moreover, plasmid-based repair
assays show increased mutations with larger deletions in WS cells
(47).
A clear sequence homology exists between the helicase domains of WRN,
Escherichia coli RecQ protein, and the yeast SGS1 protein. The E. coli RecQ helicase has been shown to have a role in
homologous recombination (48) and the Saccharomyces
cerevisiae SGS1 functions to suppress homologous recombination
(49). Five RecQ-like proteins have been identified in humans as
compared with the single RecQ helicase in E. coli and
S. cerevisiae. Among these RecQ-like proteins, the
exonuclease function of WRN is unique, suggesting that WRN and possibly
the other human RecQ-like proteins may have divergently evolved for
specialized functions. Consistent with this idea, the three syndromes
associated with mutations in three different human RecQ-like helicases,
Werner's syndrome, Bloom's syndrome, and Rothmund-Thomson syndrome,
have overlapping but markedly different phenotypes. Additionally,
complementation of sgs1 mutant yeast with BLM restores
hydroxyurea resistance and suppresses cell growth in the
top3 background, whereas WRN does not, indicating that these
proteins are not functionally equivalent (50). Furthermore, the
interactions between WRN and DNA-PKcs are not likely to be mirrored in
yeast, as this organism lacks DNA-PKcs. Therefore, it is not clear that
WRN, or any of the human RecQ-like helicases, are true functional
homologues of the E. coli RecQ or yeast SGS1.
Our results show for the first time that the catalytic subunit of
DNA-PK interacts directly with WRN, and that Ku does not compete or
disrupt the DNA-PKCS·WRN complex. The functional
consequence of WRN-DNA-PKCS interaction is surprisingly
opposite the effect of the WRN-Ku interaction. DNA-PKCS
inhibited WRN exonuclease activity, whereas Ku stimulated the same
activity. Furthermore, the interaction between Ku and WRN had little
effect on WRN helicase activity, whereas we found that
DNA-PKCS dramatically inhibits WRN helicase activity. Most
importantly, the addition of Ku relieved the DNA-PKCS
inhibition of both WRN enzymatic functions.
In addition to demonstrating a direct interaction between WRN and
DNA-PKCS, we also showed the assembly of a
WRN·DNA-PK·DNA complex. This complex appeared to be more stable
than subcomplexes, including WRN-Ku. The stability of the
WRN·DNA-PK·DNA complex suggests that the WRN-Ku and
DNA-PKCS-WRN interactions are additive, and not
competitive, with respect to WRN. Previous reports clearly showed an
interaction between WRN and Ku and a resulting stimulation of WRN
exonuclease, but not helicase, activity (16, 17, 51). Given that the
DNA-PKCS·WRN complex persisted in the presence of Ku, and
that DNA-PK is more abundant than WRN in cells, it is feasible that the
majority of WRN is associated with DNA-PKCS in
vivo. If this is the case, then the interaction between WRN and Ku
is most relevant in the context of DNA-PK.
We further report the novel finding that DNA-PK phosphorylates WRN
in vitro and is required for WRN phosphorylation in
vivo. These data establish a physiological interaction between
DNA-PK and WRN. Although we observed minor effects of phosphorylation on the exonuclease function of WRN, the physiological role of WRN
phosphorylation is still unclear. Phosphorylation may function to
facilitate the interactions with ligase after end processing is
complete, or fulfill an as yet unidentified role in NHEJ or other
process. Alternatively, the full effect of WRN phosphorylation may only
be apparent when other proteins are present. We showed that WS cells
are mildly radiation-sensitive and that this sensitivity was
complemented by WRN. Although these data do not support a requirement
for WRN in NHEJ, they suggest that WRN may function in a subset of NHEJ
events or provide functions that overlap with other proteins such as
the M/R/N complex. It is feasible that the type or context of the DSBs
dictates the specific exonuclease(s) required to process and rejoin the
break. Other enzymes may compensate for the lack of WRN with respect to
global NHEJ, whereas the WRN·DNA-PK may be specifically required to
process a class of substrates associated with aging. This class of DSBs
may involve telomeric DNA, as Ku was recently reported to localize to
telomeres in yeast and human cells (52, 53).
Taken together, our data suggest an intriguing mechanism for the
regulation of WRN activities by DNA-PK. We show that the WRN·DNA-PKCS complex is inactive with respect to
exonuclease, helicase and kinase activities. The
WRN·DNA-PKCS complex assembles on DNA termini by
associating with the DNA-bound Ku. The assembly of the
WRN·DNA-PK·DNA complex then activates the WRN exonuclease and
helicase activities, and the DNA-PKCS kinase activity (Fig. 4D). We propose that the helicase then functions to unwind
the DNA termini, allowing for the microhomology search between the two
DNA ends, and the exonuclease functions to remove unpaired bases,
allowing ligation. In this model, DNA-PK localizes WRN to DNA breaks,
switches on exonuclease and helicase activities, and acts as a scaffold
to align DNA termini for microhomology annealing and limited
exonucleolytic processing.
Interestingly, this proposed mechanism is consistent with the reported
aging phenotypes of Ku and DNA-PKCS knockout mice. Cells
from Ku70 and Ku80 knockout mice undergo premature cellular senescence,
and the animals are smaller than normal size. Moreover, Ku80 knockout
mice prematurely develop multiple characteristics of aging, reminiscent
of WS patients (54). DNA-PKCS knockout mice, by contrast,
are of normal stature and have not been reported to undergo premature
cellular senescence or prematurely develop aging characteristics. Our
data shows that WRN is inactive when bound to DNA-PKCS, and
WRN activation requires association with Ku·DNA. If this were the
case in mouse cells, then WRN would be constitutively repressed in the
absence of Ku. This would effectively deplete cells for WRN activity
and result in a phenotype reminiscent of human WS with respect to
aging. In contrast, cells lacking DNA-PKCS cannot repress
WRN activity, and WRN-Ku interactions may be sufficient for WRN
function, consequently DNA-PKCS knockout mice would not
display premature aging phenotypes. Therefore, it is formally possible
that the repression of WRN function may be causative in the observed
aging phenotype of Ku(
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, and to associate with the DNA replication complex (15). WRN was
also shown to interact with Ku, suggesting a function in DNA repair
(16, 17). The enzymatic activities of WRN clearly indicate a function
in DNA metabolism, but its specific physiological functions are not yet understood.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP using T4 polynucleotide
kinase (New England Biolabs). Approximately 50 fmol of each purified
protein was incubated with the probe for 10 min at 25 °C and
resolved by 4.5% non-denaturing Tris/glycine PAGE at 4 °C, and
visualized by autoradiography (27). Protein-DNA complexes were
cross-linked by adding glutaraldehyde to reactions (0.0625% final
concentration) after incubation for 10 min at 25 °C, and continuing
the incubation for 5 min prior to electrophoresis (28). Where noted,
polyclonal antibodies recognizing WRN were added after cross-linking
and incubated for 1-2 min prior to electrophoresis.
-32P]ATP
using T4 polynucleotide kinase as described (14). Reactions were
incubated for 10 min at 37 °C with ~100 fmol of WRN in each reaction, and the indicated amounts of Ku and DNA-PKCS.
Exonuclease assays were carried out under conditions reported
previously (14), with the same probe used for electrophoretic mobility
shift assays (EMSAs; described above). Briefly, 200 fmol of probe was
incubated for 30 min at 37 °C in 50 mM HEPES (pH 7.5),
50 mM KCl, 10 mM MgCl2, 1 mM DTT with ~20 fmol of WRN. Reaction products were
resolved on 16% PAGE-TBE gels containing 8.3 M urea.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (40K):
[in a new window]
Fig. 1.
Werner protein interacts
specifically with the catalytic subunit of DNA-PK and assembles with
DNA-PK on DNA. A, Jurkat cell nuclear extract was
immunoprecipitated (IP) with rabbit pre-immune serum
(lane 1), normal mouse IgG (lane 2),
rabbit serum recognizing WRN (lane 3), or mouse
monoclonal IgG recognizing DNA-PKCS (lane
4), or analyzed without immunoprecipitation (extract)
(lane 5). The extract or immunoprecipitates were
probed sequentially for DNA-PKCS and WRN by Western
blotting. The protein in the extracts was saturating relative to the
amount of antibody. B, 0.5 µg of purified of purified WRN,
DNA-PKCS, and Ku protein was diluted into 750 µl of
Tris-buffered saline with or without 1 µg of oligonucleotide DNA as
indicated, and immunoprecipitated with anti-WRN or
anti-DNA-PKCS antibody. The precipitates were then resolved
by SDS-PAGE and immunoblotted for DNA-PKCS and WRN.
C, EMSA in which 50 fmol of each indicated protein was
incubated with 200 fmol of a 5'-32P-labeled 35-bp
oligonucleotide and resolved by Tris/glycine electrophoresis under
non-denaturing conditions. D, EMSA, identical reactions
cross-linked with 0.06% glutaraldehyde for 5 min prior to
electrophoresis (lanes 1-5). Serial dilutions of
WRN antibody were added to cross-linked EMSA reactions 1-2 min prior
to electrophoresis (2' = 1:10,000, 3' = 1:1000, 4' = 1:100, 5' = 1:10) and the free probe
was run off the gel. The wells on each gel are indicated
(w).

View larger version (30K):
[in a new window]
Fig. 2.
Werner protein is phosphorylated by DNA-PK
in vitro and requires DNA-PK for in vivo
phosphorylation. A, autoradiogram of an in
vitro DNA-PK kinase assay, resolved by SDS-PAGE. Reactions
contained 0.5 pmol of DNA-PK and 1 pmol of WRN (lanes
1-4), or 0.2 pmol of DNA-PK and 1 pmol of WRN
(lanes 5 and 6), 0.75 µg of sheared
salmon sperm DNA, and 1 µM wortmannin where indicated.
B, Jurkat, M059J, and M059K cells were starved for phosphate
for 30 min, then labeled with [32P]orthophosphate prior
to extraction and immunoprecipitation. The phosphorylation and protein
levels were sequentially analyzed by autoradiography and
immunoblotting, respectively.

View larger version (49K):
[in a new window]
Fig. 3.
DNA-PKCS inhibits WRN exonuclease
and helicase activities but inhibition is lost in the presence of
Ku. A, WRN helicase assays containing double-stranded
DNA substrate 5'-32P-labeled 21-base oligonucleotide
annealed to a 43-base oligonucleotide as described (14).
Lane 1 is a mock reaction containing reaction
buffer and substrate. Triangles indicate increasing amounts
of protein (50, 250, and 1000 fmol), and + indicates 1000 fmol of
either DNA-PKCS or Ku or 1 µM wortmannin.
Reactions were incubated at 37 °C for 10 min with 2 mM
ATP. All reactions contained 100 fmol of WRN and were resolved by 10%
native TBE-PAGE. B, WRN exonuclease assay. All reactions
contained 5'-32P-labeled 35-bp oligonucleotide.
Lane 1 is a mock reaction containing reaction
buffer and substrate (S). Lanes 2-16
contain 100 fmol of WRN and increasing amounts of DNA-PKCS
(0, 50, 250, 500, and 1000 fmol from left to
right) as indicated by triangles.
Lanes 7-11 contain 500 fmol of Ku in each
reaction, and lanes 12-16 contain 500 fmol of Ku
and 250 µM ATP.

View larger version (28K):
[in a new window]
Fig. 4.
WS are sensitive to ionizing radiation and
sensitivity is reversed by complementation with WRN
cDNA. A, purified recombinant WRN
protein (lane 1) and equal amounts of the indicated cellular
extracts (lanes 2-5) were immunoblotted
sequentially for WRN and tubulin. B, colony formation assay
of 82-6 hTERT (wt), 76-24 hTERT (WRN
/
), and
76-24 hTERT complemented with WRN-FLAG cDNA. Cells were plated in
triplicate (500 cells/100-mm dish), irradiated, cultured for 7-12
days, stained with crystal violet, and scored. C, MTS
viability assay. Cells were plated in triplicate 96-well dishes at 1000 cells/well, irradiated, cultured for 3-9 days, and scored according to
the manufacturer's instructions. Data points are
slightly offset on the x axis to avoid overlapping
error bars. D, illustration of
DNA-PK-WRN interaction model.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
) mice.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Junko Oshima for the WRN antibody and 82-6 and 73-26 primary fibroblasts, Malgorzata Zdzienicka for the AT/HSF cell set, Akihiro Kurimasa for assistance with the survival studies, members of Pricilla Cooper's laboratory for helpful discussions, and Sandeep Burma and Janice Pluth for critically reading the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by the United States Department of Energy under Contract DE-AC03-76SF00098; by National Institutes of Health Grants AG917709 (to D. J. C.), CA50519 (to D. J. C.), AG11658 (to J. C.), and AG17242 (to J. C.); and by National Institutes of Health NIA Training Grant AG00266 (to M. B. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Laboratory of Molecular Medicine, Ohio State
University, Columbus, OH 43210-1252.
§ Present address: Palo Alto Inst. of Molecular Medicine, Mountain View, CA 94043.
¶ To whom correspondence should be addressed: Life Sciences Div., Dept. of Molecular and Cellular Biology, Lawrence Berkeley National Laboratory, Mail Stop 74-157, 1 Cyclotron Rd., Berkeley, CA 94720. Tel.: 510-495-2861; Fax: 510-486-6816; E-mail: djchen@lbl.gov.
Published, JBC Papers in Press, July 27, 2001, DOI 10.1074/jbc.M101913200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: DSB, double-strand breaks; NHEJ, nonhomologous end joining; PAGE, polyacrylamide gel electrophoresis; DNA-PK, DNA-dependent protein kinase; EMSA, electrophoretic mobility shift assay; TBE, Tris borate-EDTA; WS, Werner syndrome; M/R/N, Mre11·Rad50·NBS1; IR, ionizing radiation; hTERT, human telomerase; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (inner salt); DTT, dithiothreitol; bp, base pair(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | van Gent, D. C., Hoeijmakers, J. H., and Kanaar, R. (2001) Nat. Rev. Genet. 2, 196-206 |
| 2. | Smith, G. C., and Jackson, S. P. (1999) Genes Dev. 13, 916-934 |
| 3. | Blier, P. R., Griffith, A. J., Craft, J., and Hardin, J. A. (1993) J. Biol. Chem. 268, 7594-7601 |
| 4. | Anderson, C. W. (1993) Trends Biochem. Sci. 18, 433-437 |
| 5. | Gu, Y., Seidl, K. J., Rathbun, G. A., Zhu, C., Manis, J. P., van der Stoep, N., Davidson, L., Cheng, H. L., Sekiguchi, J. M., Frank, K., Stanhope-Baker, P., Schlissel, M. S., Roth, D. B., and Alt, F. W. (1997) Immunity 7, 653-665 |
| 6. | Zhu, C., Bogue, M. A., Lim, D. S., Hasty, P., and Roth, D. B. (1996) Cell 86, 379-389 |
| 7. | Peterson, S. R., Kurimasa, A., Oshimura, M., Dynan, W. S., Bradbury, E. M., and Chen, D. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3171-3174 |
| 8. | Kurimasa, A., Ouyang, H., Dong, L. J., Wang, S., Li, X., Cordon-Cardo, C., Chen, D. J., and Li, G. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1403-1408 |
| 9. | Salk, D., Au, K., Hoehn, H., and Martin, G. M. (1981) Cytogenet. Cell Genet. 30, 92-107 |
| 10. | Fukuchi, K., Martin, G. M., and Monnat, R. J., Jr. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5893-5897 |
| 11. | Goto, M. (2000) Clin. Exp. Rheumatol. 18, 760-766 |
| 12. | Martin, G. M., Oshima, J., Gray, M. D., and Poot, M. (1999) J. Am. Geriatr. Soc. 47, 1136-1144 |
| 13. | Gray, M. D., Shen, J. C., Kamath-Loeb, A. S., Blank, A., Sopher, B. L., Martin, G. M., Oshima, J., and Loeb, L. A. (1997) Nat. Genet. 17, 100-103 |
| 14. | Huang, S., Li, B., Gray, M. D., Oshima, J., Mian, I. S., and Campisi, J. (1998) Nat. Genet. 20, 114-116 |
| 15. | Karow, J. K., Wu, L., and Hickson, I. D. (2000) Curr. Opin. Genet. Dev. 10, 32-38 |
| 16. | Cooper, M. P., Machwe, A., Orren, D. K., Brosh, R. M., Ramsden, D., and Bohr, V. A. (2000) Genes Dev. 14, 907-912 |
| 17. | Li, B., and Comai, L. (2000) J. Biol. Chem. 275, 28349-28352 |
| 18. | Lieber, M. R. (1999) Genes Cells 4, 77-85 |
| 19. | Critchlow, S. E., and Jackson, S. P. (1998) Trends Biochem. Sci 23, 394-398 |
| 20. | Petrini, J. H. (2000) Curr. Opin. Cell Biol. 12, 293-296 |
| 21. | Yamaguchi-Iwai, Y., Sonoda, E., Sasaki, M. S., Morrison, C., Haraguchi, T., Hiraoka, Y., Yamashita, Y. M., Yagi, T., Takata, M., Price, C., Kakazu, N., and Takeda, S. (1999) EMBO J. 18, 6619-6629 |
| 22. | Dimri, G. P., Itahana, K., Acosta, M., and Campisi, J. (2000) Mol. Cell. Biol. 20, 273-285 |
| 23. | Zhao, J., Wang, J., Chen, D. J., Peterson, S. R., and Trewhella, J. (1999) Biochemistry 38, 2152-2159 |
| 24. | Chan, D. W., Mody, C. H., Ting, N. S., and Lees-Miller, S. P. (1996) Biochem. Cell Biol. 74, 67-73 |
| 25. | Cary, R. B., Peterson, S. R., Wang, J., Bear, D. G., Bradbury, E. M., and Chen, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4267-4272 |
| 26. | Moser, M. J., Kamath-Loeb, A. S., Jacob, J. E., Bennett, S. E., Oshima, J., and Monnat, R. J., Jr. (2000) Nucleic Acids Res. 28, 648-654 |
| 27. | Ausubel, F. M. (1987) Current Protocols in Molecular Biology , John Wiley & Sons, New York |
| 28. | Ting, N. S., Kao, P. N., Chan, D. W., Lintott, L. G., and Lees-Miller, S. P. (1998) J. Biol. Chem. 273, 2136-2145 |
| 29. | Chan, D. W., and Lees-Miller, S. P. (1996) J. Biol. Chem. 271, 8936-8941 |
| 30. | Allalunis-Turner, M. J., Lintott, L. G., Barron, G. M., Day, R. S., III, and Lees-Miller, S. P. (1995) Cancer Res. 55, 5200-5202 |
| 31. | Lai, J. S., and Herr, W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6958-6962 |
| 32. | Bliss, T. M., and Lane, D. P. (1997) J. Biol. Chem. 272, 5765-5773 |
| 33. | Chernikova, S. B., Wells, R. L., and Elkind, M. M. (1999) Radiat. Res. 151, 159-166 |
| 34. | Sarkaria, J. N., Tibbetts, R. S., Busby, E. C., Kennedy, A. P., Hill, D. E., and Abraham, R. T. (1998) Cancer Res. 58, 4375-4382 |
| 35. | Boulton, S., Kyle, S., and Durkacz, B. W. (2000) Eur. J. Cancer 36, 535-541 |
| 36. | Lees-Miller, S. P., Godbout, R., Chan, D. W., Weinfeld, M., Day, R. S., III, Barron, G. M., and Allalunis-Turner, J. (1995) Science 267, 1183-1185 |
| 37. | Chan, D. W., Gately, D. P., Urban, S., Galloway, A. M., Lees-Miller, S. P., Yen, T., and Allalunis-Turner, J. (1998) Int. J. Radiat. Biol. 74, 217-224 |
| 38. | Shen, J. C., Gray, M. D., Oshima, J., Kamath-Loeb, A. S., Fry, M., and Loeb, L. A. (1998) J. Biol. Chem. 273, 34139-34144 |
| 39. | Cory, A. H., Owen, T. C., Barltrop, J. A., and Cory, J. G. (1991) Cancer Commun. 3, 207-212 |
| 40. | Zolnai, A., Toth, E. B., Wilson, R. A., and Frenyo, V. L. (1998) Acta Vet. Hung. 46, 191-197 |
| 41. | Liang, F., Han, M., Romanienko, P. J., and Jasin, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5172-5177 |
| 42. | Roth, D. B., and Wilson, J. H. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 3355-3359 |
| 43. | Paull, T. T., and Gellert, M. (1998) Mol. Cell 1, 969-979 |
| 44. | Maser, R. S., Monsen, K. J., Nelms, B. E., and Petrini, J. H. (1997) Mol. Cell. Biol. 17, 6087-6096 |
| 45. | Mirzoeva, O. K., and Petrini, J. H. (2001) Mol. Cell. Biol. 21, 281-288 |
| 46. | Paull, T. T., and Gellert, M. (1999) Genes Dev. 13, 1276-1288 |
| 47. | Runger, T. M., Bauer, C., Dekant, B., Moller, K., Sobotta, P., Czerny, C., Poot, M., and Martin, G. M. (1994) J. Invest. Dermatol. 102, 45-48 |
| 48. | Kowalczykowski, S. C., Dixon, D. A., Eggleston, A. K., Lauder, S. D., and Rehrauer, W. M. (1994) Microbiol. Rev. 58, 401-465 |
| 49. | Myung, K., Datta, A., Chen, C., and Kolodner, R. D. (2001) Nat. Genet. 27, 113-116 |
| 50. | Yamagata, K., Kato, J., Shimamoto, A., Goto, M., Furuichi, Y., and Ikeda, H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8733-8738 |
| 51. | Li, B., and Comai, L. (2001) J. Biol. Chem. 276, 9896-9902 |
| 52. | Gravel, S., Larrivee, M., Labrecque, P., and Wellinger, R. J. (1998) Science 280, 741-744 |
| 53. | Hsu, H. L., Gilley, D., Blackburn, E. H., and Chen, D. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12454-12458 |
| 54. | Vogel, H., Lim, D. S., Karsenty, G., Finegold, M., and Hasty, P. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10770-10775 |
This article has been cited by other articles:
![]() |
S. M. Yannone, I. S. Khan, R.-Z. Zhou, T. Zhou, K. Valerie, and L. F. Povirk Coordinate 5' and 3' endonucleolytic trimming of terminally blocked blunt DNA double-strand break ends by Artemis nuclease and DNA-dependent protein kinase Nucleic Acids Res., June 1, 2008; 36(10): 3354 - 3365. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Li, A. Casta, R. Wang, E. Lozada, W. Fan, S. Kane, Q. Ge, W. Gu, D. Orren, and J. Luo Regulation of WRN Protein Cellular Localization and Enzymatic Activities by SIRT1-mediated Deacetylation J. Biol. Chem., March 21, 2008; 283(12): 7590 - 7598. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Brosh Jr and V. A. Bohr Human premature aging, DNA repair and RecQ helicases Nucleic Acids Res., December 3, 2007; 35(22): 7527 - 7544. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Das, I. Boldogh, J. W. Lee, J. A. Harrigan, M. L. Hegde, J. Piotrowski, N. de Souza Pinto, W. Ramos, M. M. Greenberg, T. K. Hazra, et al. The Human Werner Syndrome Protein Stimulates Repair of Oxidative DNA Base Damage by the DNA Glycosylase NEIL1 J. Biol. Chem., September 7, 2007; 282(36): 26591 - 26602. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. F. Povirk, T. Zhou, R. Zhou, M. J. Cowan, and S. M. Yannone Processing of 3'-Phosphoglycolate-terminated DNA Double Strand Breaks by Artemis Nuclease J. Biol. Chem., February 9, 2007; 282(6): 3547 - 3558. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sasakawa, T. Fukui, and S. Waga Accumulation of FFA-1, the Xenopus Homolog of Werner Helicase, and DNA Polymerase {delta} on Chromatin in Response to Replication Fork Arrest J. Biochem., July 1, 2006; 140(1): 95 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Hisama, V. A. Bohr, and J. Oshima WRN's Tenth Anniversary Sci. Aging Knowl. Environ., June 28, 2006; 2006(10): pe18 - pe18. [Abstract] [Full Text] |
||||
![]() |
S. M. Bailey and J. P. Murnane Telomeres, chromosome instability and cancer. Nucleic Acids Res., January 1, 2006; 34(8): 2408 - 2417. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Cheng, R. Kusumoto, P. L. Opresko, X. Sui, S. Huang, M. L. Nicolette, T. T. Paull, J. Campisi, M. Seidman, and V. A. Bohr Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links. Nucleic Acids Res., January 1, 2006; 34(9): 2751 - 2760. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tanaka, M. S. Mendonca, P. S. Bradshaw, D. J. Hoelz, L. H. Malkas, M. S. Meyn, and D. Gilley DNA damage-induced phosphorylation of the human telomere-associated protein TRF2 PNAS, October 25, 2005; 102(43): 15539 - 15544. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lan, S. Nakajima, K. Komatsu, A. Nussenzweig, A. Shimamoto, J. Oshima, and A. Yasui Accumulation of Werner protein at DNA double-strand breaks in human cells J. Cell Sci., September 15, 2005; 118(18): 4153 - 4162. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Livingstone, H. Ruan, J. Weiner, K. R. Clauser, P. Strack, S. Jin, A. Williams, H. Greulich, J. Gardner, M. Venere, et al. Valosin-Containing Protein Phosphorylation at Ser784 in Response to DNA Damage Cancer Res., September 1, 2005; 65(17): 7533 - 7540. [Abstract] [Full Text] [PDF] |
||||
![]() |